AngioScore Overview

  • Founded
  • 2003
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 149
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $230M
Latest Deal Amount

AngioScore General Information

Description

Developer of tools for endovascular therapy. The company develops angioplasty catheters for use in the treatment of cardiovascular and vascular disease.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Parent Company
Primary Office
  • 5055 Brandin Court
  • Fremont, CA 94538
  • United States
+1 (510) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AngioScore Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 30-Jun-2014 $230M 000.00 00000 Completed Generating Revenue
8. Secondary Transaction - Private 24-Jul-2012 00000 000.00 Completed Generating Revenue
7. Secondary Transaction - Private 000.00 Completed
6. Later Stage VC (Series F) 20-Apr-2011 0000 000.00 00000 Completed Generating Revenue
5. Later Stage VC (Series E) 09-Oct-2007 0000 000.00 00000 Completed Generating Revenue
4. Later Stage VC (Series D) 11-Apr-2006 000.00 000.00 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 19-Jul-2005 00.000 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 23-Aug-2004 $15.1M $16.8M 0000 Completed Generating Revenue
1. Early Stage VC (Series A) 28-Mar-2003 $1.63M $1.63M 00.000 Completed Product Development
To view AngioScore’s complete valuation and funding history, request access »

AngioScore Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series F 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series E 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series D 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series C 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B 6,751,590 $0.001000 8% $2.24 $2.24 1x $2.17 15.17%
Series A1 1,632,434 $0.001000 8% $1 $1 1x $1 3.55%
To view AngioScore’s complete cap table history, request access »

AngioScore Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of tools for endovascular therapy. The company develops angioplasty catheters for use in the treatment of card
Therapeutic Devices
Fremont, CA
149 As of 2014
000.00
0000 0000-00-00
000000&0 000.00

00000000

olor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
00000000000 0000000
Emeryville, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

000000 0

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse c
00000000 0000000
Wayne, PA
00 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AngioScore Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mercator MedSystems Venture Capital-Backed Emeryville, CA 00 00000 00000000000 00000
000000 0000000 Venture Capital-Backed Wayne, PA 00 000.00 00000000000 000.00
0000 000 Formerly PE-Backed Vaulx-en-Velin, France 000 0000 00000000 0000
000000 00000000 Venture Capital-Backed Wayne, PA 00 00000 000000&0 00000
0000000 0000000 00 Private Equity-Backed Burlington, MA 000 00000 00000000. 00
You’re viewing 5 of 18 competitors. Get the full list »

AngioScore Executive Team (11)

Name Title Board Seat Contact Info
Victor Hwang Managing Director
Kent Jones Senior Vice President, Regulatory and Quality
Jeff Bleam Vice President, Research & Development
Nancy Chang Advisor
Steven Frank Advisor
You’re viewing 5 of 11 executive team members. Get the full list »

AngioScore Board Members (12)

Name Representing Role Since
James Armstrong Self Board Member 000 0000
Robert Elliott Self Board Member 000 0000
You’re viewing 2 of 12 board members. Get the full list »

AngioScore Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AngioScore Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
California Technology Ventures Venture Capital Minority 000 0000 000000 0
Industry Ventures Venture Capital Minority 000 0000 000000 0
Innomed Ventures Venture Capital Minority 000 0000 000000 0
Jerusalem Global Ventures Venture Capital Minority 000 0000 000000 0
Linkagene Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »